SMARCB1 and rhabdoid tumor: This antagonistic relationship between PRC and SWI/SNF is well illustrated for the SMARCB1 deficient malignant rhabdoid tumour [135,136], and EZH2 inhibitors led to regression of malignant rhabdoid tumours in vitro and in vivo [137].